Moderna, Inc. (NASDAQ:MRNA) Given Consensus Rating of “Hold” by Analysts

Shares of Moderna, Inc. (NASDAQ:MRNA) have received a consensus rating of “Hold” from the twenty-one analysts that are presently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $79.50.

A number of research firms have weighed in on MRNA. TD Cowen reduced their target price on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research note on Friday, September 13th. Piper Sandler reiterated an “overweight” rating and issued a $69.00 target price (down previously from $115.00) on shares of Moderna in a research note on Monday, November 18th. Barclays reduced their target price on Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. Leerink Partners dropped their price target on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research report on Tuesday, September 17th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Friday, November 8th.

Insider Activity at Moderna

In other Moderna news, CFO James M. Mock sold 715 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This trade represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,379 shares of company stock valued at $158,195 over the last quarter. 15.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Moderna

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC raised its stake in shares of Moderna by 8.3% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 11,894 shares of the company’s stock worth $1,412,000 after purchasing an additional 914 shares during the last quarter. Swedbank AB raised its stake in shares of Moderna by 9.6% in the second quarter. Swedbank AB now owns 34,099 shares of the company’s stock worth $4,049,000 after purchasing an additional 2,993 shares during the last quarter. Silver Lake Advisory LLC purchased a new position in shares of Moderna in the second quarter worth about $299,000. Assenagon Asset Management S.A. raised its stake in shares of Moderna by 13.0% in the second quarter. Assenagon Asset Management S.A. now owns 7,352 shares of the company’s stock worth $873,000 after purchasing an additional 843 shares during the last quarter. Finally, Miracle Mile Advisors LLC purchased a new position in shares of Moderna in the second quarter worth about $219,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Stock Performance

NASDAQ:MRNA opened at $42.82 on Friday. The stock’s fifty day moving average is $48.62 and its 200 day moving average is $85.02. Moderna has a fifty-two week low of $35.80 and a fifty-two week high of $170.47. The firm has a market capitalization of $16.48 billion, a PE ratio of -7.36 and a beta of 1.58. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same quarter last year, the firm posted ($1.39) earnings per share. The business’s revenue was up 3.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Moderna will post -9.32 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.